Asthma and Allergy Clinical Trials

Are You Currently Taking Oral Corticosteroids (OCS) for Your Asthma?

Would you like to contribute to important new research? SUNRISE is a clinical study investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for OCS in adults with severe asthma. The study is looking for people who:

• Are between 18 and 80 years of age
• Have had an asthma diagnosis for at least 1 year
• Have been taking OCS for asthma for at least 6 months
• Have been using inhaled corticosteroids for at least a year, and a long-acting beta 2-agonist (LABA) for at least 3 months
• Have not been receiving any biologic treatment for asthma for at least 4 months
  
  

Sponsored by AstraZeneca

LEARN MORE

Now Accepting Patients for National Asthma Study

Are you a young adult between the ages of 18 and 30, African American or Black, with persistent asthma? Are you looking to get better control of your asthma? A national study is now accepting patients to test various mobile health programs. If you qualify for the study, you will be asked to use a mobile health program for about 10 weeks and complete four 30-minute questionnaires spread out over the course of one year. Everything is remote – you won’t have to come in for any study visits.

You will receive $160 for completing the study and will be given a Garmin physical activity tracker which you can keep after the study has ended.

Learn more about the study and see if you qualify.

If you have any questions, please contact us at: 734-489-1949 or theathenaproject2022@gmail.com

LEARN MORE

Latest Asthma and Allergy News

Asthma

Study Finds Puerto Rican Black Latinx Populations in the United States Have Higher Risk of Emergency Department and Urgent Care Asthma Visits Than Other Black Subgroups
Asthma disproportionately affects Black populations. But there is little research looking at asthma in Black subgroups. In a recent study, researchers studied asthma in different groups of Black adults to see if there were differences in how asthma affects them. The study included participants who identified as African American (AA/B) as well as people from multiethnic Black backgrounds (ME/B). Multiethnic Black backgrounds included Black Latinx, Caribbean, continental African, or other Black individuals. The researchers discovered that ME/B adults, especially adults who are Puerto Rican Black Latinx, were more likely to visit the emergency department or urgent care and use corticosteroids for asthma compared to AA/B adults. This suggests that asthma impacts these groups in distinct ways, highlighting the importance of considering cultural and ancestral differences in asthma research and health care.

Lower Socioeconomic Status May Help Explain Racial Disparities in Asthma and Atopic Dermatitis Prevalence
A new study looks closer at the role of socioeconomic status (SES) in explaining racial disparities in asthma and atopic dermatitis (AD). The study used data from the National Health Interview Survey (2011-2018) to look at the prevalence of these conditions in Black and white children in the United States. The results show that Black children had higher rates of AD and asthma compared to white children. When looking at the role of SES, the researchers found that SES explained 25% of the disparity in AD prevalence and explained 47% of the disparity in asthma prevalence between Black and white children. This suggests that while there are racial differences in the prevalence of these diseases, part of these disparities can be attributed to socioeconomic factors.

Food Allergy

Study Finds Association Between IgE to Common Food Allergens and Heart Disease: Here’s What You Need to Know
A recent study found that IgE to common food allergens is associated with heart disease. Misinformation about the findings of the study are being shared widely, so here are some key things you need to know:

• The study looks at sensitization, which is the presence of an allergic antibody. While sensitization is a prerequisite for food allergy, it is not the same thing as having a food allergy.
• The study looks at the association between the two factors, meaning changes in one factor can sometimes lead to changes in the other. The results do not show that IgE to common food allergens leads to heart disease.
• The study did not look at whether people had allergic reactions or were avoiding the foods they were sensitive to. This information could provide important context to the results.
• There is still a lot that is unknown about why this connection. Other factors that were not included in the study may play a role. More research is needed to understand the association.
  
  

While the study highlights a previously unknown association, the results should not cause any immediate concern for the food allergy community. People with food allergies or known IgE levels should not change their food allergy management without talking to a doctor first.

COPD

Dupixent® Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial
In a recent study (NOTUS), the biologic Dupixent® demonstrated a 34% reduction in exacerbations in people with chronic obstructive pulmonary disease (COPD). These results confirm positive results from a previous trial (BOREAS). The trial involved adults with uncontrolled COPD despite maximal standard-of-care inhalation therapy. Dupixent also showed quick and lasting improvements in lung function after three months. These improvements continued through the one-year mark. The companies behind Dupixent plan to submit this data, along with results from the BOREAS trial, to the Food and Drug Administration for potential approval later this year.

Anaphylaxis

Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (Epinephrine) Sublingual Film
Aquestive Therapeutics has started a crucial study for its product Anaphylm™. Anaphylm is an under-the-tongue epinephrine product used for severe allergic reactions. The study will compare the performance of Anaphylm to other forms of epinephrine. The goal of the study is to understand how the body absorbs and reacts to the medicine. The company aims to file Anaphylm for FDA approval in 2024, emphasizing its potential as a convenient and effective needle-free treatment for severe allergic reactions.